Literature DB >> 20088788

Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers?

Muneyuk Masuda1, T Wakasaki, Masumi Suzui, Satoshi Toh, Andrew K Joe, I B Weinstein.   

Abstract

Despite recent advancements in treatment modalities, the overall survival and quality of life of patients with head and neck squamous cell carcinoma (HNSCC) have not improved significantly over the past decade. With the increasing emergency of new biological agents, the development of novel treatment schemes based on cancer cell biology may be promising for this group of patients. We previously introduced the "oncogene addiction" concept as a rationale for molecular targeting in cancer therapy and prevention. In this context, an increasing number of preclinical studies have demonstrated that the Signal Transducers and Activators of transcription 3 (Stat3) transcription factor plays critical roles in the development and progression of a variety of tumors including HNSCC, by regulating cell proliferation, cell cycle progression, apoptosis, angiogenesis, immune evasion, Epithelial-Mesenchymal Transition (EMT) and through effects in cancer stem cells. The purpose of this review is to summarize current experimental and clinical evidence that suggest that HNSCC might be addicted to Stat3 and describe the molecular mechanisms that may explain this phenomenon. In addition, we discuss whether this addiction is an exploitable target for developing approaches for the treatment and prevention of HNSCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20088788     DOI: 10.2174/156800910790980197

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  35 in total

1.  A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.

Authors:  Takahiro Wakasaki; Muneyuki Masuda; Hiroaki Niiro; Siamak Jabbarzadeh-Tabrizi; Kumiko Noda; Tadayoshi Taniyama; Shizuo Komune; Koichi Akashi
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

Review 2.  Molecular evidence of cryptotanshinone for treatment and prevention of human cancer.

Authors:  Wenxing Chen; Yin Lu; Guangying Chen; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

3.  Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction.

Authors:  Yi Jiang; Ze-Hong Miao; Lei Xu; Bing Yu; Jing-Xu Gong; Lin-Jiang Tong; Yi Chen; Zhao-Li Zhou; Hong-Chun Liu; Yi Wang; Yue-Wei Guo; Jian Ding
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

4.  First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

Authors:  Malabika Sen; Sufi M Thomas; Seungwon Kim; Joanne I Yeh; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri; Jessica Lee; Nivedita Sahu; Sonali Joyce; Maria L Freilino; Haibin Shi; Changyou Li; Danith Ly; Srinivas Rapireddy; Jonathan P Etter; Pui-Kai Li; Lin Wang; Simion Chiosea; Raja R Seethala; William E Gooding; Xiaomin Chen; Naftali Kaminski; Kusum Pandit; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2012-06-20       Impact factor: 39.397

5.  Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.

Authors:  Fang-Ming Gu; Quan-Lin Li; Qiang Gao; Jia-Hao Jiang; Xiao-Yong Huang; Jin-Feng Pan; Jia Fan; Jian Zhou
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

6.  Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis.

Authors:  Shreeram C Nallar; Sudhakar Kalakonda; Daniel J Lindner; Robert R Lorenz; Eric Lamarre; Xiao Weihua; Dhananjaya V Kalvakolanu
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

Review 7.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

Review 8.  Stress-triggered atavistic reprogramming (STAR) addiction: driving force behind head and neck cancer?

Authors:  Muneyuki Masuda; Takahiro Wakasaki; Satoshi Toh
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

9.  Monoallelic loss of tumor suppressor GRIM-19 promotes tumorigenesis in mice.

Authors:  Sudhakar Kalakonda; Shreeram C Nallar; Sausan Jaber; Susan K Keay; Ellen Rorke; Raghava Munivenkatappa; Daniel J Lindner; Gary M Fiskum; Dhananjaya V Kalvakolanu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

Review 10.  Epithelial to mesenchymal transition in head and neck squamous cell carcinoma.

Authors:  Ashley Smith; Theodoros N Teknos; Quintin Pan
Journal:  Oral Oncol       Date:  2012-11-19       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.